Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kluft

Showing results (201-210 of 230) with videos related to

Pageof 23
Sort By:
Clinical Pharmacology and Therapeutics|February 18, 1998
Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarctionJ M van Griensven, R W Koster, J Burggraaf, et al.
Journal of Thrombosis and Haemostasis : JTH|August 13, 2003
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitusM A Van De Ree, M P M De Maat, C Kluft, et al.
Journal of the American College of Cardiology|December 1, 1990
Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarctionF Andreotti, M C Roncaglioni, D R Hackett, et al.
Thrombosis and Haemostasis|December 1, 1995
Identification and genetic analysis of a common molecular variant of histidine-rich glycoprotein with a difference of 2kD in apparent molecular weightB C Hennis, P A van Boheemen, S Wakabayashi, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|November 1, 1985
The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after traumaC Kluft, J H Verheijen, A F Jie, et al.
Journal of Drug Targeting|January 1, 1995
The preparation of tissue-type Plasminogen Activator (t-PA) containing liposomes: entrapment efficiency and ultracentrifugation damageJ L Heeremans, H R Gerritsen, S P Meusen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 11, 1999
Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled studyG W de Valk-de Roo, C D Stehouwer, P Meijer, et al.
Journal of Neurology|February 11, 1998
The Dutch Vascular Factors in Dementia Study: rationale and designF van Kooten, M L Bots, M M Breteler, et al.
British Journal of Clinical Pharmacology|August 1, 1993
Interaction study between nifedipine and recombinant tissue-type plasminogen activator in healthy subjectsA De Boer, C Kluft, F J Kasper, et al.
Metabolism: Clinical and Experimental|June 1, 1987
Effects of moderate alcohol consumption on platelet aggregation, fibrinolysis, and blood lipidsN A Pikaar, M Wedel, E J van der Beek, et al.
Pageof 23

Showing results (201-210 of 230) with videos related to

Sort By:
Pageof 23
Clinical Pharmacology and Therapeutics|February 18, 1998
Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarctionJ M van Griensven, R W Koster, J Burggraaf, et al.
Journal of Thrombosis and Haemostasis : JTH|August 13, 2003
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitusM A Van De Ree, M P M De Maat, C Kluft, et al.
Journal of the American College of Cardiology|December 1, 1990
Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarctionF Andreotti, M C Roncaglioni, D R Hackett, et al.
Thrombosis and Haemostasis|December 1, 1995
Identification and genetic analysis of a common molecular variant of histidine-rich glycoprotein with a difference of 2kD in apparent molecular weightB C Hennis, P A van Boheemen, S Wakabayashi, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|November 1, 1985
The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after traumaC Kluft, J H Verheijen, A F Jie, et al.
Journal of Drug Targeting|January 1, 1995
The preparation of tissue-type Plasminogen Activator (t-PA) containing liposomes: entrapment efficiency and ultracentrifugation damageJ L Heeremans, H R Gerritsen, S P Meusen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 11, 1999
Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled studyG W de Valk-de Roo, C D Stehouwer, P Meijer, et al.
Journal of Neurology|February 11, 1998
The Dutch Vascular Factors in Dementia Study: rationale and designF van Kooten, M L Bots, M M Breteler, et al.
British Journal of Clinical Pharmacology|August 1, 1993
Interaction study between nifedipine and recombinant tissue-type plasminogen activator in healthy subjectsA De Boer, C Kluft, F J Kasper, et al.
Metabolism: Clinical and Experimental|June 1, 1987
Effects of moderate alcohol consumption on platelet aggregation, fibrinolysis, and blood lipidsN A Pikaar, M Wedel, E J van der Beek, et al.
Pageof 23